SignaBlok presented innovative approach to diagnostic imaging of atherosclerosis at the 2015 NHLBI Innovation Conference-West
SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for rheumatoid arthritis at the 2015 ACR Annual Meeting
SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting
SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models
SignaBlok presented proof-of-concept animal data on development of novel MRI contrast agent for diagnostic imaging of atherosclerosis at the 2014 Joint Annual Meeting ISMRM-ESMRMB
SignaBlok presented proof-of-concept animal data on development of a novel ligand-independent inhibitor of TREM-1 for treatment of sepsis and lung cancer at the 2014 AACR Annual Meeting
SignaBlok presented TREM-1 program in inflammation and cancer at the 2014 Inflammation, Infection and Cancer Keystone Symposium
